PIK3CA and uterine carcinoma: Similarly, a study in PIK3CA positive primary uterine carcinomas cells, demonstrated a stronger growth inhibition by taselisib, when compared with WT cells, as well as in vivo tumor growth inhibition in mice with PIK3CA mutation (58).